These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15833886)

  • 1. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis.
    Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P
    Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
    Zhang H; Stephens LC; Kumar R
    Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
    Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
    Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.
    Zhang H; Kuang SQ; Liao L; Zhou S; Xu J
    Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
    Swanson SM; Christov K
    Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.
    Bocchinfuso WP; Hively WP; Couse JF; Varmus HE; Korach KS
    Cancer Res; 1999 Apr; 59(8):1869-76. PubMed ID: 10213494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
    Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
    Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone dependence in premalignant mammary progression.
    Medina D; Kittrell FS; Shepard A; Contreras A; Rosen JM; Lydon J
    Cancer Res; 2003 Mar; 63(5):1067-72. PubMed ID: 12615724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
    Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE
    Cancer Res; 2000 Dec; 60(24):6901-10. PubMed ID: 11156389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions.
    Pontiggia O; Rodriguez V; Fabris V; Raffo D; Bumaschny V; Fiszman G; de Kier Joffé EB; Simian M
    Breast Cancer Res Treat; 2009 Jul; 116(2):247-55. PubMed ID: 18622696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to 17beta-estradiol-stimulated mammary tumorigenesis.
    Zhang X; Shen P; Coleman M; Zou W; Loggie BW; Smith LM; Wang Z
    Anticancer Res; 2005; 25(1A):369-75. PubMed ID: 15816560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
    Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
    Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
    Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD
    Cancer Res; 2003 May; 63(10):2425-33. PubMed ID: 12750262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation.
    Gattelli A; Cirio MC; Quaglino A; Schere-Levy C; Martinez N; Binaghi M; Meiss RP; Castilla LH; Kordon EC
    Cancer Res; 2004 Aug; 64(15):5193-9. PubMed ID: 15289324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.
    Ménard S; Aiello P; Tagliabue E; Rumio C; Lollini PL; Colnaghi MI; Balsari A
    Cancer Res; 2000 Jan; 60(2):273-5. PubMed ID: 10667575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice.
    Simian M; Manzur T; Rodriguez V; de Kier Joffé EB; Klein S
    Breast Cancer Res Treat; 2009 Jan; 113(1):1-8. PubMed ID: 18183485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
    Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
    Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
    Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.